Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Validation of known and novel AKT, S6K and RSK targets by targeted MS

ABSTRACT: Based on the global SILAC and label-free phosphoproteomics experiments, we generated an inclusion list for validation of known and novel AKT, RSK and S6K targets containing the RxRxxp[ST] motif. Samples were analyzed by targeted MS using PRM.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Culture

SUBMITTER: Friedel Drepper

LAB HEAD: Prof. Dr. Bettina Warscheid

PROVIDER: PXD029633 | Pride | 2023-02-22

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	QEplus028204.raw	Raw
	QEplus028205.raw	Raw
	QEplus028206.raw	Raw
	QEplus028207.raw	Raw
	QEplus028209.raw	Raw

Items per page:

1 - 5 of 49

Similar Datasets

Label-free global phosphoproteomics experiment using PI3K-AKT-mTOR-S6K and RAF-MEK-ERK-RSK pathway activation and inhibition

Project description:The signaling network of skeletal muscle cells is controlled by a variety of protein kinases. Although many kinases are known players, their downstream targets are still largely unexplored. To gain further knowledge about the PI3K-AKT-mTOR-S6K and the RAF-MEK-ERK-RSK signaling networks in myotubes, we analyzed changes in protein phosphorylation levels upon pathway activation and direct kinase inhibition on a global scale. Based on the phosphoproteomics data, we further examined target relationships of the basophilic kinases AKT, RSK and S6K, which share the substrate recognition motif RxRxxp[ST].

2023-02-22 | PXD029678 | Pride

Quantitative phosphoproteome of contracting C2 myotubes with pharmacological intervention of the PI3K-AKT-mTOR-S6K and RAF-MEK-ERK-RSK cascades

Project description:Various protein kinases are regulating the intracellular signaling network of skeletal muscle cells. Despite that many of the involved kinases are known, their downstream targets have remained largely unexplored. To deepen our understanding of the PI3K-AKT-mTOR-S6K and the RAF-MEK-ERK-RSK signaling network in myotubes, we globally analyzed changes in protein phosphorylation levels upon kinase inhibition within these pathways. The phosphoproteomics data were used to define potential targets of the kinases AKT, RSK and S6K, which share the substrate recognition motif RxRxxp[ST].

2023-02-22 | PXD018667 | Pride

FLNc S2233 S2236 PRM analysis

Project description:Skeletal muscle is known to adapt dynamically to changes in workload by regulatory processes of the phosphatidylinositide 3-kinase (PI3K)/Akt pathway. We performed a global quantitative phosphoproteomics analysis of contracting mouse C2 myotubes treated with insulin growth factor 1 (IGF-1) or LY294002 to activate or inhibit PI3K/Akt signaling, respectively. Among the significantly regulated phosphopeptides we identified the novel extended basophilic motif RxRxxp[S/T]xxp[S] to be enriched in the set of down-regulated phosphopeptides following inhibition of PI3K/Akt signaling. Using literature-based text mining we identified the kinases Akt, serum and glucocorticoid-regulated kinase 1 (SGK1) and p70S6 kinase to be potentially involved in the phosphorylation of the first serine in the RxRxxp[S/T]xxp[S] motif, whereas no kinase targeting the serine in the +3 position was revealed. In the signaling adapter protein filamin c (FLNc) we found this novel motif in immunoglobulin (Ig)-like domain 20 which is involved in various protein interactions. Through in vitro and in cellulo kinase assays we identified Akt and protein kinase C alpha as the responsible kinases phosphorylating FLNc in this motif at the first and the second serine, respectively.

2020-06-30 | PXD009228 | Pride

Phosphoproteomics of C2C12 differentiation

Project description:Phosphoproteomic analysis of myogenesis in C2C12 myoblasts differentiating into myotubes. Four time points were analysed (0min, 30min, 24h and 5d) with four biological replicates.

2024-01-26 | PXD023413 | Pride

Phosphoproteomics-directed manipulation reveals SEC22B as an hepatocellular signaling node governing metabolic actions of glucagon

Project description:The peptide hormone glucagon is a fundamental metabolic regulator that is also being considered as a pharmocotherapeutic option for obesity and type 2 diabetes. Despite this, we know very little of how glucagon exerts its pleiotropic metabolic actions. Given that the liver is a chief site of action, we conducted in situ time-resolved liver phosphoproteomics to reveal glucagon signaling nodes. On pathway analysis of the thousands of phosphopeptides identified, we identified “vesicle transport” as a dominant signature with the vesicle trafficking protein SEC22 Homolog B (SEC22B) S137 phosphorylation being a top hit. Hepatocyte-specific loss- and gain-of-function experiments revealed that SEC22B was a key regulator of glycogen, lipid and amino acid metabolism, with SEC22B-S137 phosphorylation playing a major role in glucagon action. Mechanistically, we identified several protein binding partners of SEC22B affected by glucagon, some of which were only bound with SEC22B-S137 phosphorylation. In summary, here we demonstrate that phosphorylation of SEC22B is an hepatocellular signaling node mediating the metabolic actions of glucagon, and provide a rich resource for future investigations on the biology of glucagon action.

2024-08-29 | PXD049186 | Pride

Human FLNc-S2233/S2236 phosphorylation after EPS treatment (PRM analysis)

Project description:The actin-binding protein filamin c (FLNc) is a key mediator in the response of skeletal muscle cells to mechanical stress. In addition to its function as a structural scaffold, FLNc acts as a signaling adaptor which is phosphorylated at S2234 in its mechanosensitive domain 20 (d20) through AKT. Here, we discovered a strong dephosphorylation of FLNc-pS2234 in skeletal myotubes under acute mechanical stress, despite high AKT activity. We found that all three protein phosphatase 1 (PP1) isoforms are part of the FLNc d18-21 interactome. Enzymatic assays demonstrate that PP1 efficiently dephosphorylates FLNc-pS2234 in vitro and in cells upon PP1 activation using specific modulators. FLNc-pS2234 dephosphorylation promotes the interaction with FILIP1, a mediator for filamin degradation. Collectively, we present a model in which dephosphorylation of FLNc d20 by the dominant action of PP1c prevails over AKT activity to promote the binding of the filamin degradation-inducing factor FILIP1 during acute mechanical stress. Note that mouse FLNc S2234/S2237 correspond to S2233 and S2236 in human FLNc.

2025-05-07 | PXD053234 | Pride

Phosphoproteomics of MuSK Signaling

Project description:The development of the neuromuscular synapse depends on signaling processes which involve protein phosphorylation as a crucial regulatory event. The receptor tyrosine kinase MuSK is the key signaling molecule at the neuromuscular synapse whose activity is required for the formation of a mature and functional neuromuscular synapse. However, the signaling cascade downstream of MuSK and the regulation of the different components is still poorly understood. Here we present data from a quantitative phosphoproteomics approach to study MuSK-dependent processes. Muscle cells were stimulated with the heparansulfate proteoglycan agrin, which activates MuSK and downstream signaling events. To get an insight into the signaling dynamics we used three different time points (unstimulated, 15 min, 60 min and 4 hrs).

2014-06-05 | PXD000878 | Pride

Phosphoproteomics of MuSK Signaling

2014-06-05 | PXD000558 | Pride

FilaminC pull-down experiment from myotube lysates

Project description:This project was designed to identify a difference in the binding affinity of FILIP1 to different FLNc variants. To this end FLNc domain 1-3 and FLNc d18-21 were used as bait for a pull-down analysis.

2020-05-25 | PXD017670 | Pride

Phosphoproteomic profiling of D816V-KIT cells

Project description:Acute Myeloid Leukaemia (AML) carries a 5 year survival rate of just 24%. Toxic chemotherapy regimens remain the backbone of standard of care for AML. The KIT tyrosine kinase is a recognised AML oncogene, associated with poor outcome. We recently identified DNA-PK as a novel therapeutic target in FLT3 mutant AML. The similarity between KIT and FLT3 regulated signalling pathways led us to investigate DNA-PK in KIT-mutant AML.

2023-01-26 | PXD030005 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data